阿鲁米斯
ALMS
6.12
-0.19
-3.01%
阿鲁米斯
US · ALMS
#3337 按市值排名
上市于 2024
6.12
-0.19
-3.01%
实时 - 追踪5344个代码 - 心跳于398秒前
· 2026-10-16 19:30
✦ 量化股权信号 计算方式说明
减持
- 最近一期（2026/Q3）披露持股的机构数量减少了3家。
- 机构持股总比例下降了4.6个百分点。
机构持股
- 机构持股比例
- 92.27% -4.64pp
- 机构数量
- 238 -3
- 数据截至
- 2026/Q3 较上一报告期
持股变动 vs 资金流向
方向一致机构在上一报告期减持了股份，同时该股在最近20个交易日的主力资金呈净流出——两者方向一致。
机构持股变动数据按季度发布且存在滞后；资金流向数据为每日更新。请将其作为方向性的交叉验证参考，而非精确的择时信号。
持股人类型
Mutual Fund33.70%
VC/PE Fund30.01%
Hedge Fund26.27%
Public Company1.46%
Individual/Insider0.54%
Private Company0.42%
Government Pension Fund0.20%
Insurance Company0.17%
Other7.19%
主要股东 截至 2026-06-30
Matrix Capital Management Company, LP
11.70% · 15.14M 股
Foresite Capital Management, LLC
7.09% · 9.18M 股
BlackRock
6.35% · 8.22M 股
Samsara BioCapital LLC
5.59% · 7.24M 股
FMR
5.23% · 6.77M 股
Deep Track Capital, LP
4.90% · 6.35M 股
T. Rowe Price Group, Inc.
4.02% · 5.20M 股
Vanguard Capital Management, LLC
3.73% · 4.83M 股
venBio LLC
3.50% · 4.53M 股
Nextech Invest Ltd.
2.74% · 3.54M 股
条形长度是相对于此处列出的最大股东而言，并非相对于公司100%股权。
内部人持股
共追踪50份申报 · 41次买入 · 9次卖出
| 姓名 | 职务 | 持股比例 |
|---|---|---|
| Matrix Capital Management Company, LP | -- | 11.70% |
| David Goldstein | Chief Scientific Officer & Head of CMC | 0.18% |
| Roy Hardiman | Chief Business & Legal Officer | 0.15% |
| Martin Babler | Chairperson & CEO | 0.09% |
| Mark Bradley | Chief Development Officer | 0.05% |
| Jorn Drappa | Chief Medical Officer & Head of Research and Development | 0.03% |
| Zhengbin Yao | Independent Director | 0.02% |
| Alan Colowick | Independent Director | 0.01% |
| C. Machado | Independent Director | 0.01% |
| John Schroer | Chief Financial Officer | 0.00% |
内部人交易 最近的 Form 4 申报记录
| 日期 | 姓名 | 职务 | 类型 | 股数 | 价格 |
|---|---|---|---|---|---|
| 2026-09-07 | Samsara BioCapital LLC | -- | Open Market Acquisition | +986,721 | $10.63–11.17 |
| 2026-09-07 | Samsara BioCapital LLC | -- | Open Market Disposition | -96,131 | $10.55 |
| 2026-08-02 | Roy Hardiman | Chief Business & Legal Officer | Open Market Disposition | -2,692 | $26.37 |
| 2026-08-02 | John Schroer | Chief Financial Officer | Open Market Disposition | -3,282 | $26.37 |
| 2026-08-02 | David Goldstein | Chief Scientific Officer & Head of CMC | Open Market Disposition | -2,596 | $26.37 |
| 2026-08-02 | Jorn Drappa | Chief Medical Officer & Head of Research and Development | Open Market Disposition | -2,447 | $26.37 |
| 2026-08-02 | Sanam Pangali | Chief Legal Officer | Open Market Disposition | -1,364 | $26.37 |
| 2026-08-02 | Mark Bradley | Chief Development Officer | Open Market Disposition | -2,572 | $26.37 |
| 2026-07-05 | Sanam Pangali | Chief Legal Officer | Derivative Exercise and Sale | -5,000 | $5.06–28.00 |
| 2026-06-29 | Srinivas Akkaraju | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Srinivas Akkaraju | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Sapna Srivastava | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Sapna Srivastava | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Lynn Tetrault | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Lynn Tetrault | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | C. Machado | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | C. Machado | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-06-29 | Zhengbin Yao | Independent Director | Other Acquisition | +3,553 | -- |
| 2026-06-29 | Zhengbin Yao | Independent Director | Other Derivative Acquisition | +15,528 | $28.14 |
| 2026-05-21 | Jorn Drappa | Chief Medical Officer & Head of Research and Development | Derivative Exercise and Retained | +26,852 | $5.06–8.84 |
Form 4 申报记录，每家公司显示最新的一批。"Other Derivative Acquisition"（其他衍生品获取）类目多为限制性股票/期权归属，并非公开市场买入——具体类型见"类型"列。
报价时间 2026-10-16 19:30:04 · 仅供参考，不构成投资建议，也未考虑您的具体情况。
阿鲁米斯 讨论区 0 条评论